Reducing Vancomycin Dosage in Children on ECMO with Renal Impairment

Area of Science:

• Pediatric Critical Care Medicine
• Pharmacokinetics and Pharmacodynamics
• Infectious Disease Management

Background:

• Extracorporeal membrane oxygenation (ECMO) significantly alters drug pharmacokinetics.
• Vancomycin dosing requires careful consideration in pediatric patients undergoing ECMO.
• Limited data exists on specific vancomycin dosage adjustments for children on ECMO.

Purpose of the Study:

• To compare vancomycin pharmacokinetics in pediatric patients on ECMO versus critically ill non-ECMO patients.
• To determine appropriate vancomycin dosage adjustments for children receiving ECMO.
• To evaluate the impact of renal function on vancomycin dosing in ECMO patients.

Main Methods:

• Retrospective cohort study of pediatric patients in a cardiac intensive care unit.
• Comparison between ECMO support group and a non-ECMO control group (delayed sternal closure).
• Analysis of vancomycin trough levels and daily dosage relative to body weight (mg/kg/d).

Main Results:

• ECMO patients received significantly lower daily vancomycin doses (33.3 mg/kg/d) compared to non-ECMO patients (38.5 mg/kg/d).
• Vancomycin serum trough levels were similar and within the target range (10-20 μg/ml) for both groups.
• Lower vancomycin doses were necessary in ECMO patients with impaired renal function at treatment initiation (22.5 mg/kg/d vs. 42.1 mg/kg/d).

Conclusions:

• Pediatric patients on ECMO with initial renal impairment require lower vancomycin doses.
• Therapeutic drug monitoring of vancomycin should be initiated early in ECMO patients, even before achieving a steady state.
• Vancomycin dosing protocols may need adjustment for pediatric ECMO patients, particularly those with renal dysfunction.